<a href="https://laohu8.com/S/ONCO">Onconetix Inc.</a> Held Annual Shareholder Meeting
Onconetix Inc. held its annual meeting on December 5, 2025. Shareholders approved the issuance of up to 4,424,080 shares of Common Stock upon conversion of Series D Preferred Stock and up to 4,362,827 shares of Common Stock upon the exercise of certain warrants issued in connection with a private placement that closed on September 22, 2025. Approval was also granted for the issuance of up to 2,025,223 shares of Common Stock upon conversion of Series E Preferred Stock and up to 2,025,223 shares of Common Stock upon exercise of certain warrants related to a private placement that closed on October 1, 2025. The appointment of MaloneBailey, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. Shareholders also approved the potential adjournment of the annual meeting to solicit additional proxies if needed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120144), on December 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.